Myotonic Dystrophy — Deal Benchmarks & Valuation
Market Analysis
Myotonic Dystrophy is one of the most actively transacted indications in neurology licensing. Phase 1 deals for myotonic dystrophy carry a median total deal value of $2.0B, with upfront payments ranging from $54M to $223M. The recommended deal structure allocates approximately 7% to upfront payments and 93% to milestones.
Milestone structures for myotonic dystrophy deals allocate $923M to development milestones, $554M to regulatory milestones, and $369M to commercial milestones. Royalty rates range from 7.9% to 15.7% at the base tier, with tiered escalation reaching 11.9%-19.7% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for myotonic dystrophy licensing?
What royalty rates are standard for myotonic dystrophy deals?
How are myotonic dystrophy deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.